GlassScriptPhysician profile
Olga Shabalov
NPI 1518962992
$4,233.82
in general payments reported to CMS, 2019-2025
23 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,063 · 2020: $970 · 2021: $310 · 2022: $416 · 2023: $189 · 2024: $156 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $474.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $759.68 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $572.80 | 2019-2024 | |
| Amgen INC. | $508.38 | 2019-2025 | Repatha |
| Amarin Pharma, INC. | $424.50 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $363.23 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $282.30 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $222.13 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $218.05 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.07 | 2019-2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $139.33 | 2019-2023 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $131.21 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $66.63 | 2019-2020 | |
| Cvrx, INC. | $62.18 | 2021-2023 | Barostim Neo System |
| Gilead Sciences, INC. | $50.46 | 2019 | |
| Kestra Medical Technology Services, INC. | $48.78 | 2023 | Assure Wcd |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $35.95 | 2019 | |
| Lundbeck LLC | $32.26 | 2020 | |
| Boston Scientific Corporation | $27.73 | 2021 | |
| Arbor Pharmaceuticals, INC. | $26.46 | 2020 | |
| Merck Sharp & Dohme LLC | $24.05 | 2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $23.86 | 2019 | |
| Tactile Systems Technology INC | $18.21 | 2021 | |
| Cardiovascular Systems INC. | $17.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Shabalov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.